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Kreike and colleagues [1] examined the gene expression and
pathological characteristics of a retrospectively accrued
cohort of 97 triple-negative phenotype (TNP) (oestrogen
receptor [ER]-negative, progesterone receptor-negative, and
HER2-negative) invasive breast cancers. TNP tumours were
profiled with oligonucleotide microarrays and compared with
a control group of 102 non-TNP tumours, which were
obtained from an unrelated project. The authors then
investigated whether the TNP would accurately identify basal-
like cancers, by assessing the correlation coefficient between
the gene expression profiles of each TNP cancer and the
centroids of the molecular subgroups as defined by Hu and
colleagues [2]. As expected, the majority (91%) of TNP
tumours were classified as ‘basal-like’ tumours. However, 9%
of tumours either showed a normal-like phenotype or were
unclassifiable [1]. The authors presented a hierarchical
clustering analysis of both TNP and control cases, based on
a partial ‘intrinsic gene list’ and a different reference RNA
when compared with those reported by Hu and colleagues
[2], and observed that all of the TNP group and 18.6% of the
control non-TNP group clustered together [1]. Based on the
above results, the authors drew the provocative conclusions
that ‘basal-like tumours can be reliably defined by triple-
negative immunohistochemistry’ and that ‘triple-negative
tumours are synonymous with basal-like tumours’.
We believe that equating TNP tumours with basal-like breast
cancer is misleading [3] and, in fact, is not supported by the
data the authors themselves present. Given that only 91% of
TNP tumours displayed a significant association with the
basal-like centroid and that 18.6% of non-TNP tumours
clustered together with TNP tumours in the ‘basal-like’
cluster, a more reasonable conclusion is that the majority of,
but not all, TNP tumours have a basal-like phenotype and that
the majority of, but not all, basal-like tumours have a TNP
phenotype. Therefore, it is also reasonable to conclude that
the above findings do not demonstrate that TNP tumours are
synonymous with basal-like tumours.
One could argue that the results of the study conducted by
Kreike and colleagues [1] are, in fact, in almost complete
agreement with those of previous studies that demonstrate
that a TNP immunohistochemical (IHC) phenotype is not an
ideal surrogate for the identification of microarray-defined
basal-like breast cancers [4-9]. Based on previous expression
profiling/hierarchical clustering analysis, not only basal-like
cancers but also normal breast-like cancers harbour a TNP
phenotype at the mRNA level [8,10,11]. Importantly, normal
breast-like tumours have been shown to have a distinct
response to neoadjuvant chemotherapy [8] and prognosis
when compared with basal-like breast tumours. The only IHC
signature of basal-like breast tumours which has been
validated by expression profiling demonstrated that a panel
composed of ER, HER2, Ck 5/6, and epidermal growth factor
receptor (EGFR) can identify these tumours with 100%
specificity and 76% sensitivity [4]. In that study [4], if basal
markers (that is, Ck 5/6 and EGFR) were not included, the
specificity of the signature (that is, solely composed of ER
and HER2) would be significantly reduced with a marginal
increase in the sensitivity [4]. Furthermore, apart from the
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remarkably low prevalence of EGFR expression in TNP
tumours, the results of Kreike and colleagues [1] are in
agreement with those of several previously published
comparisons on the IHC features of basal-like tumours as
defined by expression arrays, which clearly demonstrate that
most, but certainly not all, have a TNP phenotype [8,11,12].
In fact, ER IHC expression and HER2 3+ or gene amplifi-
cation are reported to be found in 5% to 45% and 5% to
15% of basal-like tumours as defined by expression arrays,
respectively [3,8,9,11,12]. In addition, Harris and colleagues
[13] recently reported on a subgroup of HER2-amplified
breast cancers that harbour a basal-like transcriptomic
profile.
Previous studies have shown that the expression of ‘basal
markers’ (that is, Ck 5/6, Ck 14, Ck 17, and/or EGFR) is
associated with a poor prognosis [5-7,14], regardless of
hormone receptor expression. The expression of basal markers
(basal cytokeratins and EGFR) in TNP tumours (core basal
phenotype) also correlates with a worse prognosis and
identifies a clinically distinct subgroup within the TNP group
[5,7]. Moreover, it should be noted that identification of a
subgroup of tumours solely based on the lack of expression
of immunohistochemistry (for example, TNP) risks mis-
assignment based on technical artifacts [3,4].
From a technical perspective, a word of caution should be
voiced concerning the design of the study of Kreike and
colleagues [1]: slide batch spotting biases and differences in
the reference RNA used have been reported to have a
significant effect on microarray data analysis [15]. When
these biases are not corrected by additional processing and
rescaling of the data [15-17] and cases are subjected to
hierarchical clustering analysis, cluster assignment is typically
biased by the noise inherent in each slide batch and/or
reference. Hence, it is not clear to what extent the 97 TNP
samples in this study clustered together owing purely to the
similarities of their gene expression biology as opposed to the
contributions to the expression profiles induced by distinct
slide batches and/or references used for the analysis of TNP
and control groups (so-called ‘batch effect’) [15-18].
Molecular profiling undoubtedly has had a dramatic impact on
our understanding of breast cancer [4,10,11]. Given the
difficulties in applying expression array analysis to identify the
molecular subgroups in clinical practice (in particular, when
formalin-fixed paraffin-embedded samples are used), the
identification of simple IHC panels that reliably identify these
subgroups, as described by Kreike and colleagues [1], is
undeniably a meritorious effort. However, caution should be
exercised in the translation of results obtained with mRNA-
based expression analysis to IHC markers. Two of the most
pressing challenges of breast cancer research are (a) to
unravel the complexity of TNP tumours and basal-like breast
carcinomas and (b) to identify novel therapeutic targets for
these tumours. Blurring the boundaries of these two
subgroups of breast tumours by using surrogate markers
derived from microarray-based studies that are not optimally
designed may lead to misleading conclusions and serve only
to further confound the study of already enigmatic and
clinically challenging entities.
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